Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 09, 2022 17:16 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
Cidara Therapeutics Submits NDA for Rezafungin and Announces License Agreement with Melinta Therapeutics for Commercialization of Rezafungin in the U.S.
July 27, 2022 08:00 ET
|
Cidara Therapeutics, Inc.
Submitted NDA for rezafungin for candidemia and invasive candidiasis to the U.S. FDA on July 22, 2022, with an anticipated PDUFA target action date in the first quarter of 2023, if accepted for review...
Cidara Therapeutics to Host Research and Development Day
June 27, 2022 08:00 ET
|
Cidara Therapeutics, Inc.
Virtual panel discussion will highlight the company’s Cloudbreak® platform and its potential advantages in oncology Event to be held on Thursday, July 7th at 10 AM ET SAN DIEGO, June 27, 2022 ...
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 11, 2022 16:13 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
Cidara Therapeutics and Mundipharma to Present Results from Global Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and/or Invasive Candidiasis at ECCMID 2022
April 14, 2022 08:00 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO and CAMBRIDGE, United Kingdom, April 14, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX) and Mundipharma today announced that the companies will present new clinical data...
Cidara Therapeutics Announces the Completion of Dosing the First Cohort of Healthy Volunteers in the Phase 1 Trial of CD388 in Development for Universal Prevention and Treatment of Seasonal and Pandemic Influenza
March 31, 2022 08:00 ET
|
Cidara Therapeutics, Inc.
CD388 is a drug-Fc conjugate (DFC) from Cidara’s Cloudbreak® platform and is designed to transform the standard of care for seasonal influenza prevention Trial is advancing to dosing subsequent...
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
March 07, 2022 17:41 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
Cidara Therapeutics Announces FDA Acceptance of its Investigational New Drug Application for CD388 for Universal Prevention and Treatment of Influenza
February 14, 2022 08:00 ET
|
Cidara Therapeutics, Inc.
Cidara intends to initiate the Phase 1 trial in Q1 2022 Drug-Fc conjugate (DFC) CD388 leverages Cidara’s Cloudbreak® platform and has the potential to offer significant advantages over current flu...
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 06, 2022 08:00 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for...
Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
December 14, 2021 07:00 ET
|
Cidara Therapeutics, Inc.
Trial met FDA and EMA-pre-specified primary endpoints versus daily standard of care Data to support global regulatory filings in mid-2022 Cidara to host investor conference call today, December...